New Mexico AG Accuses DOJ of Delaying Jeffrey Epstein Ranch Investigation 
Iran Says It Closes Strait of Hormuz After Warning Shot at Vessel 
US, China to Hold AI Talks Ahead of Xi’s September Visit 
DOJ Subpoenas Major Law Firms in Trump Executive Order Dispute 
ASEAN Summit Faces Pressure as U.S.-Iran Conflict, South China Sea Tensions Dominate Agenda 
Germany Producer Prices Rise 1.8% in June, Missing Forecasts 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
HHS Watchdog Reports $5.56 Billion in Healthcare Fraud Recoveries as Enforcement Actions Decline 
Oil Prices Surge as U.S.-Iran Conflict Escalates, Raising Supply Fears 
US-Iran Conflict Escalates as Gulf Attacks Threaten Global Oil Supply 
EU to Propose New Rules Limiting Children's Access to Social Media 
Eduardo Bolsonaro Granted U.S. Green Card Amid Brazil Legal Battle and Tariff Dispute 
Japan PM Sanae Takaichi Unveils Growth Plan as BOJ Independence Concerns Lift Bond Yields 
US Dollar Climbs to Weekly High as Middle East Tensions Lift Treasury Yields and Safe-Haven Demand 
Civil Rights Groups Sue Trump Administration Over Childcare Funding Freeze and Influencer's Role 
Smithsonian Rejects White House Claims of ‘Anti-American’ Bias 
U.S. President Donald Trump announced Tuesday that his administration will impose a 100% tariff on all imported generic drugs beginning in 2028, giving pharmaceutical companies a two-year window before the new trade policy takes effect. The move is part of a broader effort to bring generic drug manufacturing back to the United States and reduce reliance on overseas production.
In a post on Truth Social, Trump said generic pharmaceutical imports will remain exempt from tariffs until 2028. After that, a 100% tariff will be applied to imported generic medicines, with the duty set to increase to 200% at a later stage.
According to Trump, the policy is designed to encourage drugmakers to establish manufacturing plants and expand production capacity in the United States.
“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” Trump wrote.
The latest announcement follows earlier actions by the Trump administration targeting pharmaceutical imports. Earlier this year, Trump signed a proclamation imposing a 100% tariff on imported patented pharmaceuticals and has repeatedly pushed for higher duties on drug imports as part of his broader trade strategy.
Trump has argued that increasing domestic pharmaceutical production will strengthen U.S. supply chains, improve national security, and reduce dependence on foreign manufacturers.
The president also reiterated that pharmaceutical companies could avoid the tariffs if they agree to his "most favored nation" pricing policy. Under the proposal, drugmakers would charge U.S. buyers prices comparable to those paid in other countries, an approach Trump says would lower prescription drug costs for Americans.
In addition, Trump announced tariff exemptions for companies that commit to building pharmaceutical manufacturing facilities in the United States. The administration views the combination of tariffs and investment incentives as a way to accelerate the reshoring of drug production while encouraging long-term investment in the U.S. pharmaceutical industry.
The proposed tariffs are expected to have significant implications for global pharmaceutical supply chains, generic drug manufacturers, and healthcare costs as companies evaluate whether to shift production to the United States before the new duties take effect.
